Bayesian Trial Submissions Could Consume More FDA Resources, CDRH Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Device center statisticians currently spend at most 5%-10% of their time and effort evaluating Bayesian statistical analyses in premarket submissions, but the center continues to ramp up its resources to deal with a potential influx relying on the advanced technique.